Share Price | Aptus Pharma Ltd Stock Analysis & Recommendation

Q: Why is Aptus Pharma Ltd falling/rising?

As of 07-Feb, Aptus Pharma Ltd's stock price is falling, currently at 246.70, reflecting a decrease of 5.0 points or 1.99%. The stock has been underperforming relative to the benchmark Sensex, which has gained 1.59% over the past week while Aptus Pharma has declined by 6.98%. This trend of decline is further emphasized by the fact that the stock has experienced consecutive losses over the last five days, resulting in an overall drop of 8.34% during this period.Additionally, today's performance indicates that the stock has underperformed its sector by 1.19%. The trading activity shows a significant decrease in investor participation, with delivery volume dropping by 44.44% compared to the five-day average. Although the stock is trading above its 20-day, 50-day, 100-day, and 200-day moving averages, it is below its 5-day moving average, suggesting a short-term weakness. Overall, these factors contribute to the current downward trend in Aptus Pharma Ltd's stock price.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

20.0 k (150.00%) Volume

Shareholding (Dec 2025)

FII

0.00%

Held by 0 FIIs

DII

0.00%

Held by 0 DIIs

Promoter

72.89%

Why is Aptus Pharma Ltd falling/rising?

07-Feb-2026

As of 07-Feb, Aptus Pharma Ltd's stock price is at 246.70, down 1.99% and has declined 6.98% over the past week, underperforming the Sensex. The stock has seen consecutive losses for five days, with a significant drop in investor participation and short-term weakness indicated by its moving averages.

View full answer

Which are the latest news on Aptus Pharma?

08-Feb-2026

No latest news for Aptus Pharma found.

Compare Aptus Pharma with Similar Stocks

Aarey Drugs Natural Capsules Brooks Lab.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Loading Valuation Snapshot...

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

INR 173 Cr (Micro Cap)

P/E

57.00

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.28

Return on Equity

13.64%

Price to Book

7.96

Revenue and Profits:

Net Sales:

(Quarterly Results - )

Net Profit:

Total Returns

Total Returns (Price + Dividend)

Dividend Yield (0%)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

77.99%

6 Months

0.0%

1 Year

0.0%

2 Years

0.0%

3 Years

0.0%

4 Years

0.0%

5 Years

0.0%

Aptus Pharma for the last several years.

Risk Adjusted Returns v/s

Returns Beta

Beta has not been calculated since enough price history is not available

News & Corporate Actions

News

No Recent News for the Company

Announcements

Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018

10-Jan-2026 | Source : BSE

Compliance Certificate under Regulation 74 (5) of SEBI (DP) Regulations 2018

Press Release- Aptus Pharma Expands OTC Presence In Gujarat Strengthens Cosmeceutical Portfolio

12-Dec-2025 | Source : BSE

Intimation pursuant to Regulation 30 of the SEBI (LODR) Regulations 2015 regarding Press release - Aptus Pharma expands OTC presence in Gujarat Strengthens Cosmeceutical Portfolio

Regulation 30 Disclosure - Entry Into The Urology Therapy Segment

21-Nov-2025 | Source : BSE

Regulation 30 Disclosure - Entry into the Urology Therapy Segment

Corporate Actions

BOARD MEETING

No Upcoming Board Meetings

DIVIDEND

No Dividend history available

SPLITS

No Splits history available

BONUS

No Bonus history available

RIGHTS

No Rights history available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

EBIT Growth (5y)

EBIT to Interest (avg)

2.91

Debt to EBITDA (avg)

1.71

Net Debt to Equity (avg)

Sales to Capital Employed (avg)

0.82

Tax Ratio

27.80%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

28.87%

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

7.80

EV to EBIT

36.32

EV to EBITDA

34.33

EV to Capital Employed

10.49

EV to Sales

6.64

PEG Ratio

Dividend Yield

ROCE (Latest)

28.87%

ROE (Latest)

13.64%

Technicals key factors

Indicator

Weekly

Monthly

No records

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2025

Shareholding Compare (%holding)

Majority shareholders

Promoters

Pledged Promoter Holdings

None

Mutual Funds

Held by 0 Schemes

FIIs

Held by 0 FIIs

Promoter with highest holding

Kapilbhai Hasmukhbhai Chandarana (11.3%)

Highest Public shareholder

Saint Capital Fund (4.29%)

Individual Investors Holdings

22.97%

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "alert": "No Quarterly Results declared by Aptus Pharma"
  },
  {
    "link": "half-yearly",
    "btn_text": "All Half Yearly Results",
    "header": "Half Yearly Results Snapshot (Standalone) - Sep'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "Not Applicable: The company has declared_date for only one period",
        "dir": 0
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "Not Applicable: The company has declared_date for only one period",
        "dir": 0
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Sep'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "14.38",
          "val2": "9.76",
          "chgp": "47.34%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "2.93",
          "val2": "1.98",
          "chgp": "47.98%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.43",
          "val2": "0.11",
          "chgp": "290.91%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "1.75",
          "val2": "1.31",
          "chgp": "33.59%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "20.38%",
          "val2": "20.29%",
          "chgp": "0.09%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "nine-monthly",
    "btn_text": "All Nine Monthly Results",
    "alert": "No Nine Monthly Results declared by Aptus Pharma"
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Standalone) - Mar'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "Not Applicable: The company has declared_date for only one period",
        "dir": 0
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "Not Applicable: The company has declared_date for only one period",
        "dir": 0
      }
    ],
    "table": {
      "header": [
        "Mar'25",
        "Mar'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "24.56",
          "val2": "17.86",
          "chgp": "37.51%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "4.75",
          "val2": "1.54",
          "chgp": "208.44%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.47",
          "val2": "0.24",
          "chgp": "95.83%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "2.96",
          "val2": "0.80",
          "chgp": "270.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "19.34%",
          "val2": "8.62%",
          "chgp": "10.72%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Half Yearly Results Snapshot (Standalone) - Sep'25

Sep'25

Sep'24

Change(%)

Net Sales

14.38

9.76

47.34%

Operating Profit (PBDIT) excl Other Income

2.93

1.98

47.98%

Interest

0.43

0.11

290.91%

Exceptional Items

0.00

Standalone Net Profit

1.75

1.31

33.59%

Operating Profit Margin (Excl OI)

20.38%

20.29%

0.09%

Values in Rs Cr.

Compare with Peers

Net Sales

Not Applicable: The company has declared_date for only one period

Standalone Net Profit

Not Applicable: The company has declared_date for only one period

All Half Yearly Results

Annual Results Snapshot (Standalone) - Mar'25

Mar'25

Mar'24

Change(%)

Net Sales

24.56

17.86

37.51%

Operating Profit (PBDIT) excl Other Income

4.75

1.54

208.44%

Interest

0.47

0.24

95.83%

Exceptional Items

0.00

Standalone Net Profit

2.96

0.80

270.00%

Operating Profit Margin (Excl OI)

19.34%

8.62%

10.72%

Values in Rs Cr.

Compare with Peers

Net Sales

Not Applicable: The company has declared_date for only one period

Standalone Net Profit

Not Applicable: The company has declared_date for only one period

All Annual Results

Company CV

About Aptus Pharma Ltd

Aptus Pharma Ltd

Micro Cap

Pharmaceuticals & Biotechnology

No Details Available.

Company Coordinates

No Company Details Available

Aptus Pharma

1Day

52 Week

CASH

FII

DII

Promoter

Why is Aptus Pharma Ltd falling/rising?

Watch in Real-Time

Which are the latest news on Aptus Pharma?

Compare Aptus Pharma with Similar Stocks

MarketsMojo — Loved in India, Now Global

Dashboard

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

Returns Beta

News

Announcements

Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018

Press Release- Aptus Pharma Expands OTC Presence In Gujarat Strengthens Cosmeceutical Portfolio

Regulation 30 Disclosure - Entry Into The Urology Therapy Segment

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Dec 2025

Shareholding Compare (%holding)

Half Yearly Results Snapshot (Standalone) - Sep'25

Annual Results Snapshot (Standalone) - Mar'25

About Aptus Pharma Ltd

Company Coordinates